



Abridged Adjusted Consolidated Financial Statements

The following abridged consolidated financial statements and notes have been prepared as described in Note 1 in this appendix. While prepared based on the principles of Chinese Accounting Standards (ASBE), they do not contain all of the information which either ASBE or IFRS would require for a complete set of financial statements, and should be read in conjunction with the consolidated financial statements of both ADAMA Ltd. and Adama Agricultural Solutions Ltd. as filed with the Shenzhen and Tel Aviv Stock Exchanges, respectively.

Relevant income statement items contained in this release are also presented on an “Adjusted” basis, which exclude items that are of a one-time or non-cash/non-operational nature that do not impact the ongoing performance of the business, and reflect the way the Company’s management and the Board of Directors view the performance of the Company internally. The Company believes that excluding the effects of these items from its operating results allows management and investors to effectively compare the true underlying financial performance of its business from period to period and against its global peers.

Abridged Consolidated Income Statement for the Fourth Quarter

<i>Adjusted¹</i>	Q4 2024 USD (m)	Q4 2023 USD (m)	Q4 2024 RMB (m)	Q4 2023 RMB (m)
Revenues	1,113	1,136	7,965	8,119
Cost of Sales	806	882	5,768	6,304
Other costs	27	9	193	67
Gross profit	280	245	2,003	1,748
<i>% of revenue</i>	<i>25.2%</i>	<i>21.5%</i>	<i>25.2%</i>	<i>21.5%</i>
Selling & Distribution expenses	153	160	1,092	1,145
General & Administrative expenses	40	40	284	283
Research & Development expenses	13	15	96	110
Other operating expenses	(1)	5	(6)	35
Total operating expenses	205	220	1,466	1,574
<i>% of revenue</i>	<i>18.4%</i>	<i>19.4%</i>	<i>18.4%</i>	<i>19.4%</i>
Operating income (EBIT)	75	24	537	174
<i>% of revenue</i>	<i>6.7%</i>	<i>2.1%</i>	<i>6.7%</i>	<i>2.1%</i>
Financial expenses	61	89	439	636
Income (loss) before taxes	14	(65)	98	(462)
Taxes on Income	71	36	510	260
Net loss	(58)	(101)	(412)	(722)
<i>% of revenue</i>	<i>(5.2%)</i>	<i>(8.9%)</i>	<i>(5.2%)</i>	<i>(8.9%)</i>
Adjustments	91	(22)	653	(159)
Reported net loss	(149)	(79)	(1,065)	(563)
<i>% of revenue</i>	<i>(13.4%)</i>	<i>(6.9%)</i>	<i>(13.4%)</i>	<i>(6.9%)</i>
Adjusted EBITDA	137	95	982	676
<i>% of revenue</i>	<i>12.3%</i>	<i>8.3%</i>	<i>12.3%</i>	<i>8.3%</i>
Adjusted EPS²				
– Basic	(0.0247)	(0.0434)	(0.1767)	(0.3099)
– Diluted	(0.0247)	(0.0434)	(0.1767)	(0.3099)
Reported EPS⁵				
– Basic	(0.0639)	(0.0338)	(0.4572)	(0.2418)
– Diluted	(0.0639)	(0.0338)	(0.4572)	(0.2418)

¹ For an analysis of the differences between the adjusted income statement items and the income statement items as reported in the financial statements, see below “Analysis of Gaps between Adjusted Income Statement and Income Statement in Financial Statements”.

² The number of shares used to calculate both basic and diluted earnings per share in both Q4 2024 and 2023 is 2,329.8 million shares.



Abridged Consolidated Income Statement for the Full Year

<i>Adjusted³</i>	FY 2024 USD (m)	FY 2023 USD (m)	FY 2024 RMB (m)	FY 2023 RMB (m)
Revenues	4,141	4,661	29,488	32,779
Cost of Sales	3,044	3,549	21,677	24,977
Other costs	35	52	252	366
Gross profit	1,061	1,060	7,558	7,436
<i>% of revenue</i>	<i>25.6%</i>	<i>22.7%</i>	<i>25.6%</i>	<i>22.7%</i>
<i>Selling & Distribution expenses</i>	652	700	4,643	4,928
<i>General & Administrative expenses</i>	141	145	1,006	1,018
<i>Research & Development expenses</i>	58	69	416	483
<i>Other operating expenses</i>	(2)	5	(15)	35
Total operating expenses	850	918	6,051	6,464
<i>% of revenue</i>	<i>20.5%</i>	<i>19.7%</i>	<i>20.5%</i>	<i>19.7%</i>
Operating income (EBIT)	212	141	1,507	973
<i>% of revenue</i>	<i>5.1%</i>	<i>3.0%</i>	<i>5.1%</i>	<i>3.0%</i>
Financial expenses	285	348	2,029	2,451
Loss before taxes	(74)	(207)	(522)	(1,479)
Taxes on Income	133	30	946	213
Net loss	(206)	(236)	(1,468)	(1,691)
<i>% of revenue</i>	<i>(5.0%)</i>	<i>(5.1%)</i>	<i>(5.0%)</i>	<i>(5.2%)</i>
Adjustments	201	(11)	1,435	(85)
Reported net loss	(407)	(225)	(2,903)	(1,606)
<i>% of revenue</i>	<i>(9.8%)</i>	<i>(4.8%)</i>	<i>(9.8%)</i>	<i>(4.9%)</i>
Adjusted EBITDA	469	407	3,340	2,844
<i>% of revenue</i>	<i>11.3%</i>	<i>8.7%</i>	<i>11.3%</i>	<i>8.7%</i>
Adjusted EPS⁴				
– Basic	(0.0885)	(0.1013)	(0.6302)	(0.7260)
– Diluted	(0.0885)	(0.1013)	(0.6302)	(0.7260)
Reported EPS⁷				
– Basic	(0.1749)	(0.0964)	(1.2461)	(0.6893)
– Diluted	(0.1749)	(0.0964)	(1.2461)	(0.6893)

³ For an analysis of the differences between the adjusted income statement items and the income statement items as reported in the financial statements, see below "Analysis of Gaps between Adjusted Income Statement and Income Statement in Financial Statements".

⁴ The number of shares used to calculate both basic and diluted earnings per share in FY 2024 and 2023 is 2,329.8 million shares.



Abridged Consolidated Balance Sheet

	December 31 2024 USD (m)	December 31 2023 USD (m)	December 31 2024 RMB (m)	December 31 2023 RMB (m)
Assets				
Current assets:				
Cash at bank and on hand	505	689	3,631	4,881
Bills and accounts receivable	1,283	1,306	9,223	9,251
Inventories	1,553	1,848	11,165	13,089
Other current assets, receivables and prepaid expenses	264	339	1,899	2,401
Total current assets	3,605	4,182	25,917	29,622
Non-current assets:				
Fixed assets, net	1,636	1,772	11,760	12,547
Rights of use assets	78	88	557	625
Intangible assets, net	1,373	1,457	9,871	10,320
Deferred tax assets	180	226	1,292	1,602
Other non-current assets	92	97	663	690
Total non-current assets	3,359	3,640	24,142	25,784
Total assets	6,964	7,823	50,060	55,406
Liabilities				
Current liabilities:				
Loans and credit from banks and other lenders	971	1,134	6,979	8,031
Bills and accounts payable	748	743	5,374	5,263
Other current liabilities	787	791	5,660	5,600
Total current liabilities	2,506	2,668	18,013	18,894
Long-term liabilities:				
Loans and credit from banks and other lenders	301	407	2,167	2,886
Debentures	879	977	6,320	6,919
Deferred tax liabilities	39	42	283	297
Employee benefits	76	95	544	672
Other long-term liabilities	520	538	3,742	3,813
Total long-term liabilities	1,816	2,060	13,056	14,587
Total liabilities	4,322	4,727	31,069	33,481
Equity				
Total equity	2,642	3,096	18,991	21,924
Total liabilities and equity	6,964	7,823	50,060	55,406



Abridged Consolidated Cash Flow Statement for the Fourth Quarter

	Q4 2024 USD (m)	Q4 2023 USD (m)	Q4 2024 RMB (m)	Q4 2023 RMB (m)
Cash flow from operating activities:				
Cash flow from operating activities	126	293	898	2,092
Cash flow from operating activities	126	293	898	2,092
Investing activities:				
Acquisitions of fixed and intangible assets	(49)	(93)	(349)	(663)
Net cash received from disposal of fixed assets, intangible assets and others	4	0	30	3
Other investing activities	4	(16)	31	(115)
Cash flow used for investing activities	(40)	(108)	(288)	(775)
Financing activities:				
Receipt of loans from banks and other lenders	56	203	399	1,473
Repayment of loans from banks and other lenders	(174)	(308)	(1,245)	(2,202)
Interest payment and other	(47)	(55)	(338)	(392)
Other financing activities	(10)	(76)	(72)	(541)
Cash flow used for financing activities	(176)	(235)	(1,256)	(1,662)
Effects of exchange rate movement on cash and cash equivalents	0	1	100	(79)
Net change in cash and cash equivalents	(91)	(50)	(545)	(423)
Cash and cash equivalents at the beginning of the period	589	736	4,129	5,281
Cash and cash equivalents at the end of the period	499	686	3,584	4,857
Free Cash Flow	38	130	272	989



Abridged Consolidated Cash Flow Statement for the Full Year

	FY 2024 USD (m)	FY 2023 USD (m)	FY 2024 RMB (m)	FY 2023 RMB (m)
Cash flow from operating activities:				
Cash flow from operating activities	528	356	3,761	2,618
Cash flow from operating activities	528	356	3,761	2,618
Investing activities:				
Acquisitions of fixed and intangible assets	(200)	(337)	(1,424)	(2,370)
Net cash received from disposal of fixed assets, intangible assets and others	38	6	273	40
Acquisition of subsidiaries	0	(22)	-	(148)
Other investing activities	0	13	(3)	90
Cash flow used for investing activities	(162)	(339)	(1,154)	(2,388)
Financing activities:				
Receipt of loans from banks and other lenders	290	1,004	2,066	7,030
Repayment of loans from banks and other lenders	(679)	(589)	(4,834)	(4,176)
Interest payment and other	(158)	(176)	(1,127)	(1,244)
Dividends to shareholders	-	(9)	-	(63)
Other financing activities	(9)	(167)	(64)	(1,173)
Cash flow used for financing activities	(556)	63	(3,959)	374
Effects of exchange rate movement on cash and cash equivalents	3	0	79	28
Net change in cash and cash equivalents	(187)	79	(1,273)	632
Cash and cash equivalents at the beginning of the period	686	607	4,857	4,225
Cash and cash equivalents at the end of the period	499	686	3,584	4,857
Free Cash Flow	217	(147)	1,549	(923)



Notes to Abridged Consolidated Financial Statements

Note 1: Basis of preparation

Basis of presentation and accounting policies: The abridged consolidated financial statements for the quarters ended December 31, 2024 and 2023 incorporate the financial statements of ADAMA Ltd. and of all of its subsidiaries (the “Company”), including Adama Agricultural Solutions Ltd. (“Solutions”) and its subsidiaries.

The Company has adopted the Accounting Standards for Business Enterprises (ASBE) issued by the Ministry of Finance (the “MoF”) and the implementation guidance, interpretations and other relevant provisions issued or revised subsequently by the MoF (collectively referred to as “ASBE”).

The abridged consolidated financial statements contained in this release are presented in both Chinese Renminbi (RMB), as the Company’s shares are traded on the Shenzhen Stock Exchange, as well as in United States dollars (\$) as this is the major currency in which the Company’s business is conducted. For the purposes of this release, a customary convenience translation has been used for the translation from RMB to US dollars, with Income Statement and Cash Flow items being translated using the quarterly average exchange rate, and Balance Sheet items being translated using the exchange rate at the end of the period.

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated.

Note 2: Abridged Financial Statements

For ease of use, the financial statements shown in this release have been abridged as follows:

Abridged Consolidated Income Statement:

- “Gross profit” in this release is revenue less costs of goods sold, taxes and surcharges, inventory impairment and other idleness charges (in addition to those already included in costs of goods sold); part of the idleness charges is removed in the Adjusted financial statements
- “Other operating expenses” includes impairment losses (not including inventory impairment); gain (loss) from disposal of assets and non-operating income and expenses
- “Operating expenses” in this release differ from those in the formally reported financial statements in that certain transportation costs have been reclassified from COGS to Operating Expenses.
- “Financial expenses” includes net financing expenses and gains/losses from changes in fair value.

Abridged Consolidated Balance Sheet:

- “Other current assets, receivables and prepaid expenses” includes financial assets held for trading; financial assets in respect of derivatives; prepayments; other receivables; and other current assets
- “Fixed assets, net” includes fixed assets and construction in progress
- “Intangible assets, net” includes intangible assets and goodwill
- “Other non-current assets” includes other equity investments; long-term equity investments; long-term receivables; investment property; and other non-current assets
- “Loans and credit from banks and other lenders” includes short-term loans and non-current liabilities due within one year
- “Other current liabilities” includes financial liabilities in respect of derivatives; payables for employee benefits, taxes, interest, dividends and others; advances from customers and other current liabilities
- “Other long-term liabilities” includes long-term payables, provisions, deferred income and other non-current liabilities



Income Statement Adjustments

	Q4 2024 USD (m)	Q4 2023 USD (m)	Q4 2024 RMB (m)	Q4 2023 RMB (m)
Reported Net Loss	(149)	(79)	(1,065)	(563)
<u>Adjustments to COGS & Operating Expenses:</u>				
1. Amortization of acquisition-related PPA and other acquisition related costs	4	4	26	28
2. Amortization of Transfer assets received and written-up due to 2017 ChemChina-Syngenta transaction (non-cash)	5	5	38	35
3. Accelerated depreciation	1	1	10	6
4. Incentive plans	-	(1)	-	(4)
5. ASBEs classifications COGS impact	(3)	(22)	(20)	(158)
6. ASBEs classifications OPEX impact	3	22	20	158
7. Restructuring and advisory costs	19	9	134	66
8. Fixed assets impairment	90	33	644	237
9. Soil and water cleanup and remediation	1	-	10	-
Total Adjustments to Operating Income (EBIT)	120	51	861	367
Total Adjustments to EBITDA	20	9	142	63
<u>Adjustments to Financing Expenses:</u>				
12. Non-cash adjustment related to put option revaluations and release of holdback	(10)	(72)	(71)	(518)
13. Other financing expenses	(1)	(2)	(10)	(11)
<u>Adjustments to Taxes:</u>				
Taxes impact	(18)	-	(126)	3
Total adjustments to Net loss	91	(22)	653	(159)
Adjusted Net Loss	(58)	(101)	(412)	(722)



	FY 2024 USD (m)	FY 2023 USD (m)	FY 2024 RMB (m)	FY 2023 RMB (m)
Reported Net loss	(407)	(225)	(2,903)	(1,606)
<u>Adjustments to COGS & Operating Expenses:</u>				
1. Amortization of acquisition-related PPA and other acquisition related costs	15	17	106	116
2. Amortization of Transfer assets received and written-up due to 2017 ChemChina-Syngenta transaction (non-cash)	21	20	147	143
3. Accelerated depreciation	4	3	32	22
4. Incentive plans	-	(3)	-	(21)
5. ASBEs classifications COGS impact	(90)	(87)	(637)	(610)
6. ASBEs classifications OPEX impact	90	87	637	610
7. Restructuring and advisory costs	44	9	315	66
8. Fixed assets impairment	90	33	644	237
9. Soil and water cleanup and remediation	18	-	131	-
10. Expenses related to legal claims	36	-	255	-
11. Registration impairment and update of registration depreciation	28	-	196	-
Total Adjustments to Operating Income (EBIT)	256	79	1,826	562
Total Adjustments to EBITDA	100	7	712	53
<u>Adjustments to Financing Expenses:</u>				
12. Non-cash adjustment related to put options revaluation and release of holdback	(40)	(83)	(283)	(594)
13. Other financing expenses	8	(6)	59	(42)
<u>Adjustments to Taxes:</u>				
Taxes impact	(23)	(2)	(167)	(12)
Total adjustments to Net loss	201	(11)	1,435	(85)
Adjusted Net loss	(206)	(236)	(1,468)	(1,691)

Notes:

- Amortization of acquisition-related PPA and other acquisition related costs:**
 - Amortization of Legacy PPA of 2011 acquisition of Solutions (non-cash):** Under ASBE, since the third combined reporting for Q3 2017, the Company has inherited the historical "legacy" amortization charge that ChemChina previously was incurring in respect of its acquisition of Solutions in 2011. This amortization is done in a linear manner on a quarterly basis, most of which will have been completed by the end of 2020.
 - Amortization of acquisition-related PPA (non-cash) and other acquisition-related costs:** Related mainly to the non-cash amortization of intangible assets created as part of the Purchase Price Allocation (PPA) on acquisitions, with no impact on the ongoing performance of the companies acquired, as well as other M&A-related costs.
- Amortization of Transfer assets received and written-up due to 2017 ChemChina-Syngenta transaction (non-cash):** The proceeds from the Divestment of crop protection products in connection with the approval by the EU Commission of the acquisition of Syngenta by ChemChina, net of taxes and transaction expenses, were paid to Syngenta in return for the transfer of a portfolio of products in Europe of similar nature and economic value. Since the products acquired from Syngenta are of the same nature and with the same net economic value as those divested, and since in 2018 the Company adjusted for the one-time gain that it made on the divested products, the additional amortization charge incurred due to the written-up value of the acquired assets is also adjusted to present a consistent view of Divestment and Transfer transactions, which had no net impact on the underlying economic performance of the Company. These additional amortization charges will continue until 2032 but at a reducing rate, yet will still be at a meaningful level until 2028.
- Accelerated depreciation:** These charges relate to accelerated depreciation attributed to the upgrade & relocation programs in China and Israel, in which production assets located in the old production sites in Huai'An and Beer-Sheva are in relocation process to new sites. Since some older production assets may not be able to be relocated, or are not operational, these are depreciated over a shorter period.
- Incentive plans:** ADAMA granted certain of its employees, a long-term incentive (LTI) in the form of 'phantom' awards linked to the Company's share price. As such, the Company records an expense, or recognizes income, depending on the fluctuation in the Company's share price, regardless of award exercises. To neutralize the impact of such share price movements on the measurement of the Company's performance



and expected employee compensation and to reflect the existing phantom awards, in the Company's adjusted financial performance, the LTI is presented on an equity-settled basis in accordance with the value of the existing plan at the grant date.

5. & 6. **ASBEs classifications COGS impact:** according to the ASBE guidelines [IAS 37], certain items (specifically certain transportation costs) are classified under COGS.
7. **Restructuring and advisory costs:** The Company initiated its Fight Forward transformation plan in early 2024. Part of the plan includes restructuring its organizational structure, workforce and managerial processes, and as a result thereof, the Company recorded restructuring and advisory costs.
8. **Fixed assets impairment:** As part of the Company's strategic direction to enhance operational efficiency, the Company decided to focus on high-performing facilities. Consequently, after evaluating their net book value and recoverable amount, the Company recorded impairments related to certain facilities. In 2023, the impairment was recorded for a subsidiary's facilities due to changes in the markets and upgrade in technology.
9. **Soil and water cleanup and remediation:** a wholly-owned indirect subsidiary of the Company filed with Israel's Ministry of Environmental Protection a remediation plan regarding its plant in Be'er Sheva in Q2 2024. During Q3 and Q4 2024 additional expenses were recorded regarding the Company's sites in Israel and Brazil.
10. **Expenses related to legal claims:** Legal claims related to product liabilities was settled in 2024 and incurred expenses.
11. **Registration impairment and update of registration depreciation:** This is mainly related to the management's strategic decision to increase focus on products in line with the optimization of the Company's portfolio, and hence to focus on the quality of business to achieve a better sales mix of higher margin products.
12. Non-cash, non-recurring income due to revaluation of put options attributed to minority stake in subsidiaries in both 2024 and 2023 and release of holdback related to the original acquisition in 2023.
13. Other financing expenses: Expenses mainly deriving from tax claims surcharges and inflation.



Exchange Rate Data for the Company's Principal Functional Currencies

	December 31			Q4 Average			FY Average		
	2024	2023	Change	2024	2023	Change	2024	2023	Change
EUR/USD	1.041	1.106	(5.9%)	1.067	1.076	(0.8%)	1.082	1.081	0.0%
USD/BRL	6.192	4.841	(27.9%)	5.843	4.953	(18.0%)	5.390	4.995	(7.9%)
USD/PLN	4.101	3.935	(4.2%)	4.037	4.107	1.7%	3.981	4.204	5.3%
USD/ZAR	18.762	18.563	(1.1%)	17.858	18.744	4.7%	18.326	18.446	0.7%
AUD/USD	0.621	0.682	(9.0%)	0.652	0.651	0.3%	0.660	0.664	(0.7%)
GBP/USD	1.254	1.274	(1.6%)	1.282	1.240	3.3%	1.278	1.243	2.8%
USD/ILS	3.647	3.627	(0.6%)	3.698	3.819	3.2%	3.701	3.687	(0.4%)
USD S 3M	4.31%	5.33%		4.50%	5.38%	0.87 bp	5.06%	5.38%	

	December 31			Q4 Average			FY Average		
	2024	2023	Change	2024	2023	Change	2024	2023	Change
USD/RMB	7.483	7.083	5.7%	7.632	7.146	6.8%	7.702	7.042	9.4%
EUR/RMB	7.188	7.834	(8.2%)	7.156	7.686	(6.9%)	7.120	7.614	(6.5%)
RMB/BRL	0.861	0.684	(26.0%)	0.817	0.693	(17.8%)	0.757	0.709	(6.7%)
RMB/PLN	0.571	0.556	(2.7%)	0.564	0.575	1.8%	0.559	0.597	6.3%
RMB/ZAR	2.610	2.621	0.4%	2.496	2.623	4.9%	2.574	0.597	1.9%
AUD/RMB	4.463	4.834	(7.7%)	4.669	4.650	0.4%	4.697	4.677	0.4%
GBP/RMB	9.016	9.024	(0.1%)	9.172	8.864	3.5%	9.098	8.752	4.0%
RMB/ILS	0.507	0.512	0.9%	0.517	0.534	3.3%	0.520	0.524	0.7%
RMB L 3M	1.69%	2.53%	(33.4%)	1.81%	2.46%	(26.2%)	1.99%	2.32%	(14.2%)



Forward looking statement:

This press release published by ADAMA Ltd. or ADAMA Agricultural Solutions Ltd. (together the "Company") is for marketing and information purposes only, and contains forward-looking statements which are based on Company's management's beliefs and assumptions and on information currently available to the Company's management. By this press release, the Company does not intend to give, and the press release does not constitute, professional or business advice or an offer or recommendation to perform any transaction in the Company's securities. The accuracy, completeness and/or adequacy of the content of this press release, as well as any estimation and/or assessment included in this press release, if at all, is not warranted or guaranteed and the Company disclaims any intention and/or obligation to comply with such content. The Company shall not be liable for any loss, claim, liability or damage of any kind resulting from your reliance on, or reference to, any detail, fact or opinion presented herein. The Company's assessments are based on the information available to the Company as of the date hereof, and may not be realized or be realized in a different manner than the Company estimates, inter alia, due to factors out of the Company's control, including the risk factors listed in the Company's annual reports and changes in the industry or potential operations of the Company's competitors. Any content contained herein shall not constitute or be construed as any regulatory, valuation, legal, tax, accounting and investment advice or any advice of any kind or any part of it, nor shall they constitute or be construed as any recommendation, solicitation, offer or commitment (or any part of it) to buy, sell, subscribe for or underwrite any securities, provide any credit or insurance or engage in any transactions. Before entering into any transactions, you shall ensure that you fully understand the potential risks and returns of such transactions. Before making such decisions, you shall consult the advisors you think necessary, including your accountant, investment advisor and legal and tax specialists. The Company and its affiliates, controlling persons, directors, officials, partners, employees, agents, representatives or their advisors shall not assume any responsibilities of any kind (including negligence or others) for the use of and reliance on such information by you or any person to whom such information are provided.